GenSight Biologics S.A. (SIGHT.PA)

EUR 0.29

(-3.52%)

Market Cap (In EUR)

34.91 Million

Revenue (In EUR)

1.26 Million

Net Income (In EUR)

-26.22 Million

Avg. Volume

306.72 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.28-0.598
PE
-
EPS
-
Beta Value
2.33
ISIN
FR0013183985
CUSIP
F4374K117
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Laurence Rodriguez
Employee Count
-
Website
https://www.gensight-biologics.com
Ipo Date
2016-07-13
Details
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.